NSG 552 - Exam 2 - Psychopharmacology (Latest 2026/2027) Wilkes University | Grade A | Verified Answers
NSG552 / NSG 552 EXAM 2 (LATEST )
PSYCHOPHARMACOLOGY • GRADE A QUESTIONS AND VERIFIED ANSWERS
100% CORRECT • WILKES UNIVERSITY
100-Question Comprehensive Examination • 7 Sections • Aligned with AACN Essentials of Master's Education in Nursing
and Advanced Psychopharmacology Competencies (2026/2027 Edition)
Exam Blueprint: 100 questions distributed across seven core psychopharmacology domains. Cognitive
distribution: 20% recall, 50% application, 30% analysis (clinical reasoning). Format: 75% scenario-based
clinical decision-making and 25% direct knowledge. Each question includes four options (A-D) with one verified
correct answer and a 2-4 sentence rationale integrating NSG 552 curriculum, AACN Essentials, and
psychopharmacology principles.
Section 1: Principles of Psychopharmacology
Q1: A 42-year-old female with major depressive disorder is started on paroxetine 20 mg daily. The
prescriber orders pharmacogenomic testing prior to dose escalation. Which cytochrome P450
enzyme phenotype, if identified as a poor metabolizer, would most significantly increase this
patient's risk for SSRI-related adverse effects such as serotonin syndrome and QT prolongation?
A. CYP2D6 poor metabolizer *[CORRECT]*
B. CYP1A2 ultra-rapid metabolizer
C. CYP2C9 normal metabolizer
D. CYP3A4 intermediate metabolizer
Correct Answer: A
Rationale: Paroxetine is metabolized primarily by CYP2D6 and is itself a potent CYP2D6 inhibitor. A
CYP2D6 poor metabolizer phenotype results in markedly reduced clearance, elevated plasma
concentrations, and increased risk of SSRI toxicity including serotonin syndrome, hyponatremia, and QT
prolongation. CYP1A2 ultra-rapid metabolism would lower drug levels rather than raise them. CYP2C9 and
CYP3A4 are not the primary determinants of paroxetine disposition. NSG 552 curriculum emphasizes
pharmacogenomic-guided SSRI dosing per CPIC guidelines.
Page 1 | NSG 552 Exam 2 - Psychopharmacology - 100% Verified
,NSG 552 - Exam 2 - Psychopharmacology (Latest 2026/2027) Wilkes University | Grade A | Verified Answers
Q2: A patient is prescribed an antidepressant that is a substrate of P-glycoprotein (P-gp), an efflux
transporter at the blood-brain barrier. Which statement best describes the impact of P-gp on CNS
drug concentrations?
A. P-gp actively pumps drugs out of the CNS, reducing brain concentrations relative to
plasma. *[CORRECT]*
B. P-gp facilitates drug entry into the CNS by binding to transport receptors.
C. P-gp has no effect on CNS drug levels because it acts only in the liver.
D. P-gp inhibition always results in decreased therapeutic efficacy.
Correct Answer: A
Rationale: P-glycoprotein is an ATP-dependent efflux transporter expressed at the luminal surface of brain
capillary endothelial cells. It actively transports substrates such as many antidepressants, antipsychotics,
and opioids back into the blood, limiting CNS exposure. Inhibition of P-gp can increase CNS concentrations
and risk of neurotoxicity. P-gp does not facilitate drug entry and is expressed not only in liver but also
intestine, kidney, and BBB. NSG 552 pharmacokinetics module stresses transporter-mediated drug
interactions as a core competency.
Q3: A clinician initiates therapy with a drug that exhibits first-pass metabolism of approximately
80% and a bioavailability of 20%. Which pharmacokinetic concept most accurately explains this
observation?
A. Extensive hepatic metabolism prior to systemic circulation reduces oral bioavailability.
*[CORRECT]*
B. Poor gastrointestinal absorption prevents drug entry into plasma.
C. P-glycoprotein in the gut lumen is the sole determinant of oral bioavailability.
D. High protein binding decreases the free fraction available for distribution.
Correct Answer: A
Rationale: First-pass (presystemic) metabolism refers to drug metabolism occurring in the gut wall and liver
before the drug reaches systemic circulation. An 80% first-pass effect reduces bioavailability to 20%,
meaning only one-fifth of the administered dose reaches systemic plasma. Poor absorption would also
reduce bioavailability but is a separate mechanism. P-gp contributes but is not the sole determinant. Protein
binding affects distribution, not bioavailability. NSG 552 principles module covers bioavailability and the
impact of the first-pass effect on route selection.
Page 2 | NSG 552 Exam 2 - Psychopharmacology - 100% Verified
,NSG 552 - Exam 2 - Psychopharmacology (Latest 2026/2027) Wilkes University | Grade A | Verified Answers
Q4: Which pharmacokinetic parameter is most useful for designing a once-daily dosing regimen
for an antipsychotic?
A. Half-life (t1/2) *[CORRECT]*
B. Time to maximum concentration (Tmax)
C. Area under the curve (AUC)
D. Maximum concentration (Cmax)
Correct Answer: A
Rationale: Half-life determines the dosing interval required to maintain therapeutic plasma concentrations
within the therapeutic window. A drug with a half-life of approximately 24 hours is suitable for once-daily
dosing, whereas shorter half-lives require divided doses. Tmax reflects absorption rate, AUC reflects total
exposure, and Cmax reflects peak concentration, none of which directly dictate dosing frequency. NSG 552
principles module stresses the relationship between half-life, steady state (4-5 half-lives), and dosing interval
design.
Q5: A 67-year-old male with schizophrenia has been stable on haloperidol decanoate 100 mg IM
every 4 weeks for two years. He develops acute renal failure requiring hemodialysis. Which
pharmacokinetic change is most clinically relevant in guiding continued dosing?
A. Haloperidol is primarily hepatically metabolized; renal failure has minimal impact on
clearance. *[CORRECT]*
B. Haloperidol is dialyzable, so the dose must be supplemented after each dialysis session.
C. Renal failure increases haloperidol protein binding, requiring dose reduction.
D. Haloperidol is contraindicated in renal failure and must be discontinued.
Correct Answer: A
Rationale: Haloperidol undergoes extensive hepatic metabolism via glucuronidation and CYP3A4, with renal
excretion of metabolites. Significant renal impairment has minimal impact on parent drug clearance, and
haloperidol is not substantially removed by hemodialysis. No dose supplementation post-dialysis is needed.
However, metabolites may accumulate, so monitoring for adverse effects remains important. NSG 552
curriculum emphasizes organ-specific clearance considerations in dose adjustment.
Q6: A patient taking warfarin 5 mg daily is prescribed fluoxetine 20 mg daily for new-onset
depression. Two weeks later, the INR is 4.2 (target 2-3). What is the most likely mechanism of this
drug interaction?
A. Fluoxetine inhibits CYP2C9, reducing warfarin metabolism and elevating INR. *[CORRECT]*
B. Fluoxetine displaces warfarin from plasma proteins, increasing free fraction.
C. Fluoxetine induces CYP3A4, accelerating warfarin clearance.
D. Fluoxetine antagonizes vitamin K epoxide reductase, potentiating warfarin.
Correct Answer: A
Rationale: Fluoxetine and its metabolite norfluoxetine are potent inhibitors of CYP2D6 and moderate
inhibitors of CYP2C9 and CYP3A4. Warfarin's more potent S-enantiomer is metabolized by CYP2C9;
inhibition increases INR and bleeding risk. While protein displacement occurs transiently, the sustained INR
elevation is driven by metabolic inhibition. Fluoxetine does not induce CYP3A4 or directly inhibit vitamin K
epoxide reductase. NSG 552 drug-interaction module prioritizes CYP450-mediated interactions.
Page 3 | NSG 552 Exam 2 - Psychopharmacology - 100% Verified
, NSG 552 - Exam 2 - Psychopharmacology (Latest 2026/2027) Wilkes University | Grade A | Verified Answers
Q7: Therapeutic drug monitoring of lithium is ordered 12 hours after the last dose. Which
statement best explains the rationale for the standardized 12-hour trough level?
A. Lithium distribution into the CNS is slow; the 12-hour level best reflects steady-state
concentrations at the site of action. *[CORRECT]*
B. Lithium is metabolized by the liver, so a 12-hour level reflects hepatic clearance.
C. The 12-hour level corresponds to peak concentration and maximum efficacy.
D. Lithium is highly protein-bound, requiring trough measurement for accuracy.
Correct Answer: A
Rationale: Lithium distributes slowly into tissues, and the standard 12-hour post-dose trough level minimizes
the influence of distribution kinetics and reflects steady-state concentrations that correlate with both efficacy
and toxicity. Lithium is not hepatically metabolized but is excreted unchanged by the kidneys. Peak levels
occur 1-2 hours post-dose but correlate poorly with clinical effect. Lithium is not protein-bound. NSG 552
mood-stabilizer module emphasizes standardized TDM protocols for lithium safety.
Q8: A prescriber is counseling a patient with bipolar I disorder on the teratogenic risk of
divalproex sodium. Which statement reflects the standard of care regarding pregnancy and
valproate?
A. Valproate is contraindicated in pregnancy due to neural tube defects and should be
switched before conception if possible. *[CORRECT]*
B. Valproate is safe throughout pregnancy when combined with folic acid 1 mg daily.
C. Valproate is only teratogenic in the third trimester and can be used in the first two trimesters.
D. Valproate is safer than lithium in pregnancy and is the preferred mood stabilizer.
Correct Answer: A
Rationale: Valproate carries an FDA black box warning for teratogenicity, with neural tube defect risk of
approximately 6-9% and reduced IQ in offspring. It should be avoided in women of childbearing potential
unless absolutely necessary, with effective contraception and preconception switching to a safer agent such
as lurasidone or quetiapine. Folic acid supplementation reduces but does not eliminate risk. Lithium has a
lower teratogenic risk than valproate, particularly Ebstein's anomaly (0.05-0.1%). NSG 552 curriculum aligns
with AACN Essentials on reproductive pharmacotherapy safety.
Page 4 | NSG 552 Exam 2 - Psychopharmacology - 100% Verified
NSG552 / NSG 552 EXAM 2 (LATEST )
PSYCHOPHARMACOLOGY • GRADE A QUESTIONS AND VERIFIED ANSWERS
100% CORRECT • WILKES UNIVERSITY
100-Question Comprehensive Examination • 7 Sections • Aligned with AACN Essentials of Master's Education in Nursing
and Advanced Psychopharmacology Competencies (2026/2027 Edition)
Exam Blueprint: 100 questions distributed across seven core psychopharmacology domains. Cognitive
distribution: 20% recall, 50% application, 30% analysis (clinical reasoning). Format: 75% scenario-based
clinical decision-making and 25% direct knowledge. Each question includes four options (A-D) with one verified
correct answer and a 2-4 sentence rationale integrating NSG 552 curriculum, AACN Essentials, and
psychopharmacology principles.
Section 1: Principles of Psychopharmacology
Q1: A 42-year-old female with major depressive disorder is started on paroxetine 20 mg daily. The
prescriber orders pharmacogenomic testing prior to dose escalation. Which cytochrome P450
enzyme phenotype, if identified as a poor metabolizer, would most significantly increase this
patient's risk for SSRI-related adverse effects such as serotonin syndrome and QT prolongation?
A. CYP2D6 poor metabolizer *[CORRECT]*
B. CYP1A2 ultra-rapid metabolizer
C. CYP2C9 normal metabolizer
D. CYP3A4 intermediate metabolizer
Correct Answer: A
Rationale: Paroxetine is metabolized primarily by CYP2D6 and is itself a potent CYP2D6 inhibitor. A
CYP2D6 poor metabolizer phenotype results in markedly reduced clearance, elevated plasma
concentrations, and increased risk of SSRI toxicity including serotonin syndrome, hyponatremia, and QT
prolongation. CYP1A2 ultra-rapid metabolism would lower drug levels rather than raise them. CYP2C9 and
CYP3A4 are not the primary determinants of paroxetine disposition. NSG 552 curriculum emphasizes
pharmacogenomic-guided SSRI dosing per CPIC guidelines.
Page 1 | NSG 552 Exam 2 - Psychopharmacology - 100% Verified
,NSG 552 - Exam 2 - Psychopharmacology (Latest 2026/2027) Wilkes University | Grade A | Verified Answers
Q2: A patient is prescribed an antidepressant that is a substrate of P-glycoprotein (P-gp), an efflux
transporter at the blood-brain barrier. Which statement best describes the impact of P-gp on CNS
drug concentrations?
A. P-gp actively pumps drugs out of the CNS, reducing brain concentrations relative to
plasma. *[CORRECT]*
B. P-gp facilitates drug entry into the CNS by binding to transport receptors.
C. P-gp has no effect on CNS drug levels because it acts only in the liver.
D. P-gp inhibition always results in decreased therapeutic efficacy.
Correct Answer: A
Rationale: P-glycoprotein is an ATP-dependent efflux transporter expressed at the luminal surface of brain
capillary endothelial cells. It actively transports substrates such as many antidepressants, antipsychotics,
and opioids back into the blood, limiting CNS exposure. Inhibition of P-gp can increase CNS concentrations
and risk of neurotoxicity. P-gp does not facilitate drug entry and is expressed not only in liver but also
intestine, kidney, and BBB. NSG 552 pharmacokinetics module stresses transporter-mediated drug
interactions as a core competency.
Q3: A clinician initiates therapy with a drug that exhibits first-pass metabolism of approximately
80% and a bioavailability of 20%. Which pharmacokinetic concept most accurately explains this
observation?
A. Extensive hepatic metabolism prior to systemic circulation reduces oral bioavailability.
*[CORRECT]*
B. Poor gastrointestinal absorption prevents drug entry into plasma.
C. P-glycoprotein in the gut lumen is the sole determinant of oral bioavailability.
D. High protein binding decreases the free fraction available for distribution.
Correct Answer: A
Rationale: First-pass (presystemic) metabolism refers to drug metabolism occurring in the gut wall and liver
before the drug reaches systemic circulation. An 80% first-pass effect reduces bioavailability to 20%,
meaning only one-fifth of the administered dose reaches systemic plasma. Poor absorption would also
reduce bioavailability but is a separate mechanism. P-gp contributes but is not the sole determinant. Protein
binding affects distribution, not bioavailability. NSG 552 principles module covers bioavailability and the
impact of the first-pass effect on route selection.
Page 2 | NSG 552 Exam 2 - Psychopharmacology - 100% Verified
,NSG 552 - Exam 2 - Psychopharmacology (Latest 2026/2027) Wilkes University | Grade A | Verified Answers
Q4: Which pharmacokinetic parameter is most useful for designing a once-daily dosing regimen
for an antipsychotic?
A. Half-life (t1/2) *[CORRECT]*
B. Time to maximum concentration (Tmax)
C. Area under the curve (AUC)
D. Maximum concentration (Cmax)
Correct Answer: A
Rationale: Half-life determines the dosing interval required to maintain therapeutic plasma concentrations
within the therapeutic window. A drug with a half-life of approximately 24 hours is suitable for once-daily
dosing, whereas shorter half-lives require divided doses. Tmax reflects absorption rate, AUC reflects total
exposure, and Cmax reflects peak concentration, none of which directly dictate dosing frequency. NSG 552
principles module stresses the relationship between half-life, steady state (4-5 half-lives), and dosing interval
design.
Q5: A 67-year-old male with schizophrenia has been stable on haloperidol decanoate 100 mg IM
every 4 weeks for two years. He develops acute renal failure requiring hemodialysis. Which
pharmacokinetic change is most clinically relevant in guiding continued dosing?
A. Haloperidol is primarily hepatically metabolized; renal failure has minimal impact on
clearance. *[CORRECT]*
B. Haloperidol is dialyzable, so the dose must be supplemented after each dialysis session.
C. Renal failure increases haloperidol protein binding, requiring dose reduction.
D. Haloperidol is contraindicated in renal failure and must be discontinued.
Correct Answer: A
Rationale: Haloperidol undergoes extensive hepatic metabolism via glucuronidation and CYP3A4, with renal
excretion of metabolites. Significant renal impairment has minimal impact on parent drug clearance, and
haloperidol is not substantially removed by hemodialysis. No dose supplementation post-dialysis is needed.
However, metabolites may accumulate, so monitoring for adverse effects remains important. NSG 552
curriculum emphasizes organ-specific clearance considerations in dose adjustment.
Q6: A patient taking warfarin 5 mg daily is prescribed fluoxetine 20 mg daily for new-onset
depression. Two weeks later, the INR is 4.2 (target 2-3). What is the most likely mechanism of this
drug interaction?
A. Fluoxetine inhibits CYP2C9, reducing warfarin metabolism and elevating INR. *[CORRECT]*
B. Fluoxetine displaces warfarin from plasma proteins, increasing free fraction.
C. Fluoxetine induces CYP3A4, accelerating warfarin clearance.
D. Fluoxetine antagonizes vitamin K epoxide reductase, potentiating warfarin.
Correct Answer: A
Rationale: Fluoxetine and its metabolite norfluoxetine are potent inhibitors of CYP2D6 and moderate
inhibitors of CYP2C9 and CYP3A4. Warfarin's more potent S-enantiomer is metabolized by CYP2C9;
inhibition increases INR and bleeding risk. While protein displacement occurs transiently, the sustained INR
elevation is driven by metabolic inhibition. Fluoxetine does not induce CYP3A4 or directly inhibit vitamin K
epoxide reductase. NSG 552 drug-interaction module prioritizes CYP450-mediated interactions.
Page 3 | NSG 552 Exam 2 - Psychopharmacology - 100% Verified
, NSG 552 - Exam 2 - Psychopharmacology (Latest 2026/2027) Wilkes University | Grade A | Verified Answers
Q7: Therapeutic drug monitoring of lithium is ordered 12 hours after the last dose. Which
statement best explains the rationale for the standardized 12-hour trough level?
A. Lithium distribution into the CNS is slow; the 12-hour level best reflects steady-state
concentrations at the site of action. *[CORRECT]*
B. Lithium is metabolized by the liver, so a 12-hour level reflects hepatic clearance.
C. The 12-hour level corresponds to peak concentration and maximum efficacy.
D. Lithium is highly protein-bound, requiring trough measurement for accuracy.
Correct Answer: A
Rationale: Lithium distributes slowly into tissues, and the standard 12-hour post-dose trough level minimizes
the influence of distribution kinetics and reflects steady-state concentrations that correlate with both efficacy
and toxicity. Lithium is not hepatically metabolized but is excreted unchanged by the kidneys. Peak levels
occur 1-2 hours post-dose but correlate poorly with clinical effect. Lithium is not protein-bound. NSG 552
mood-stabilizer module emphasizes standardized TDM protocols for lithium safety.
Q8: A prescriber is counseling a patient with bipolar I disorder on the teratogenic risk of
divalproex sodium. Which statement reflects the standard of care regarding pregnancy and
valproate?
A. Valproate is contraindicated in pregnancy due to neural tube defects and should be
switched before conception if possible. *[CORRECT]*
B. Valproate is safe throughout pregnancy when combined with folic acid 1 mg daily.
C. Valproate is only teratogenic in the third trimester and can be used in the first two trimesters.
D. Valproate is safer than lithium in pregnancy and is the preferred mood stabilizer.
Correct Answer: A
Rationale: Valproate carries an FDA black box warning for teratogenicity, with neural tube defect risk of
approximately 6-9% and reduced IQ in offspring. It should be avoided in women of childbearing potential
unless absolutely necessary, with effective contraception and preconception switching to a safer agent such
as lurasidone or quetiapine. Folic acid supplementation reduces but does not eliminate risk. Lithium has a
lower teratogenic risk than valproate, particularly Ebstein's anomaly (0.05-0.1%). NSG 552 curriculum aligns
with AACN Essentials on reproductive pharmacotherapy safety.
Page 4 | NSG 552 Exam 2 - Psychopharmacology - 100% Verified
